Will Government Efforts to Derail Patentable Subject Matter Status Quo Derail Its Efforts to Promote Personalized Medicine? (PDF)
President Obama -- in his January 20, 2015 State of the Union address -- declared Personalized Medicine as a technology he would like to pursue. Here we examine developments in the Federal Circuit (which ruled in a related Myriad case in December 2014), the Supreme Court and the Executive Branch which meddled in the Myriad case (coming out against the USPTO's position), all in light of this growing, national interest in Personalized Medicine.
Dov Greenbaum is Director of the Zvi Meitar Institute for Legal Implications of Emerging Technologies at the Radzyner Law School, Interdisciplinary Center, Herzliya, Israel (IDC). Dov is also an Assistant Professor (adj) in the Department of Molecular Biophysics and Biochemistry at Yale University and a is a practicing intellectual property attorney. Dov has degrees and postdoctoral fellowships from Yale, UC Berkeley, Stanford, and Eidgenössische Technische Hochschule Zürich (ETH Zürich).
Ask the LexisNexis experts - and get a complete answer based on today's law.
An authoritative analysis of important cases, codes, statutes, rulings, emerging issues or legal topics is available now - through LexisNexis Emerging Issues Analysis. The brain trust of LexisNexis authors - thousands of recognized authorities who develop the respected Matthew Bender®, Mealey's and Martindale-Hubbell® treatises and articles - produce this highly specific content. Each commentary covers an important case, code, statute, ruling or emerging issue such as subprime, nanotechnology, or climate change. More current and concentrated than treatises and more analytical than news, Emerging Issues Analysis bridges the information gap between the two, providing quick expert analysis of current developments in law.
Emerging Issues Analysis PDFs should be purchased individually or accessed through Lexis.com if you have a subscription.